Biocryst Pharmaceuticals (BCRX) Income from Continuing Operations (2010 - 2026)
Biocryst Pharmaceuticals (BCRX) posted Income from Continuing Operations of 721812000.0 for Q1 2026, down 393.6% on a QoQ basis from 245845000.0 in Q4 2025, and down 2255762.5% year-over-year from N/an in Q1 2025.
Biocryst Pharmaceuticals (BCRX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 721812000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 2255762.5% year-over-year to 721812000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 457983000.0 (down 756.52% YoY) and the FY2025 annual result came in at 263861000.0, up 396.87% from the prior year.
- Income from Continuing Operations was 721812000.0 for Q1 2026 at Biocryst Pharmaceuticals, down from 245845000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 245845000.0 in Q4 2025 and bottomed at 721812000.0 in Q1 2026.
- A 5-year average of 60028647.06 and a median of 36149000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations surged 1017.5% — and 2026, when it slumped 2255762.5%.
- Biocryst Pharmaceuticals' Income from Continuing Operations stood at 71541000.0 in 2022, then gained by 13.71% to 61731000.0 in 2023, then jumped by 56.59% to 26795000.0 in 2024, then jumped by 1017.5% to 245845000.0 in 2025, then sank by 393.6% to 721812000.0 in 2026.
- Business Quant data shows BCRX's Income from Continuing Operations at 721812000.0 in Q1 2026, 245845000.0 in Q4 2025, and 12899000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Biocryst Pharmaceuticals | 2.27 Bn | 2.20 Bn | 151.04 Mn | -721.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -721.81 Mn |
| Dec 31, 2025 | 245.85 Mn |
| Sep 30, 2025 | 12.90 Mn |
| Jun 30, 2025 | 5.09 Mn |
| Mar 31, 2025 | 32,000.00 |
| Dec 31, 2024 | -26.80 Mn |
| Sep 30, 2024 | -14.03 Mn |
| Jun 30, 2024 | -12.67 Mn |
| Mar 31, 2024 | -35.38 Mn |
| Dec 31, 2023 | -61.73 Mn |
| Sep 30, 2023 | -36.15 Mn |
| Jun 30, 2023 | -75.33 Mn |
| Mar 31, 2023 | -53.33 Mn |
| Dec 31, 2022 | -71.54 Mn |
| Sep 30, 2022 | -42.52 Mn |
| Jun 30, 2022 | -58.86 Mn |
| Mar 31, 2022 | -74.20 Mn |
| Dec 31, 2021 | -17.78 Mn |
| Sep 30, 2021 | -58.80 Mn |
| Jun 30, 2021 | -43.20 Mn |